Added to YB: 2026-07-22
Pitch date: 2026-07-20
NVO [neutral]
Novo Nordisk A/S
+0.08%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.5T
Pitch Price
DKK 49.34
Price Target
N/A
Dividend
3.55%
EV/EBITDA
9.03
P/E
12.04
EV/Sales
4.83
Sector
Pharmaceuticals
Category
growth
Show full summary:
Novo Nordisk A/S: The Big Bad Bull
NVO (trimmed position): Sold ½ to fund PayPal bet on disappointing execution. GLP-1 leader but Lilly crashed oral pill party; Pfizer/Amgen coming. Risks: price collapse, insulin cannibalization (Vertex/Sana stem-cells by 2029). Wants more M&A (Sana, Structure). P/E 11 'a joke,' MAG7 potential. Still 5% position.
Read full article (3 min)